MAPLE GROVE, Minn., March 29, 2024 /PRNewswire/ -- Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced the recent launch of Methimazole Tablets, USP, 5 mg and 10 mg. The Methimazole Tablet market had U.S. sales of approximately $36.8 million for the 12 months ending December 2023 according to IQVIA. The Therapeutic Equivalence (TE) code for the product is AB, and the original Reference Listed Drug (RLD) was the brand Tapazole®*.
In November the federal National Science Foundation awarded a $700,000 research grant to Hospi so that it could expand use of the only FDA-cleared device for rectal delivery of medications. The early results look promising.